MASTER INDEX — Portfolio Table of Contents

PART A: PORTFOLIO OVERVIEW AND NAVIGATION

Vol	Title	Primary Content	Reviewer Audience
I	Executive Summary	Overview, Master Index, Authority Matrix	Clerks, Staff Attorneys, Initial Reviewers
II	Scientific Dissertation	Peer-reviewed research, methodology, reproducibility	Scientific Experts, Amici
III	Security & Zero Trust	PQC Architecture, Secure Enclave, Merkle DAG Ledger	CISOs, Security Auditors
IV	Software Architecture	R Package Architecture, COBOL Controller, REST API	Technical Experts, IT Specialists
V	Regulatory	FDA Software Lifecycle, Design Controls, Traceability	FDA Reviewers, QMS Auditors
VI	Artificial Intelligence	Scientific Assimilation Engine, XAI, Hallucination Detection	ML Engineers, Ethics Boards
VII	Reproducibility	Docker/Nix Builds, Provenance Ledger, FAIR Metadata	Bioinformaticians, Auditors
VIII	Litigation & Evidence	Evidence Chain, Exhibit Generation, Expert Witness Workflow	Court, Opposing Counsel
IX	End-to-End Genomic Pipeline	23andMe → PRS Engine → Secure Evidence Ledger	Pipeline Developers, Clinicians
X	Reference Materials	Master Bibliography, Acronym Index, Glossary	All Reviewers

All volumes use unified canonical identifiers. FIG. 14, TABLE 17, ALG. 4, MOD. 8, PAT. FIG. 14, FDA V&V-14, and EXH. 14 all trace to the same PRS computation concept.

PART B: VOLUME I — TABLE OF CONTENTS

Front Matter

FM-1. Title Page and Portfolio Identifier
FM-2. Certification of Authenticity and Integrity
FM-3. Confidentiality Designation and Redaction Index
FM-4. Master Authority Matrix (CP, SG, DA, SR, LF Domains)
FM-5. Document Control and Version History
FM-6. List of Contributing Authors and Affiliations
FM-7. Correspondence and Service List

Chapter 1: Portfolio Summary and Core Propositions

1.1. Executive Summary of the Scientific Dissertation (Cross-Ref: Vol. II, Ch. 1–4)
1.2. Summary of Patent Portfolio and Invention Families (Cross-Ref: Vol. III, Spec. 1–N)
1.3. Overview of Proposed Legal Theories (Cross-Ref: Vol. V, Ch. 2–5)
- 1.3.1. Genomic Information as Property Under Takings Clause Novel Theory
- 1.3.2. Due Process Implications of AI Accommodation Refusal Novel Theory
- 1.3.3. SSA Obligation to Accept AI-Based Accommodation Novel Theory
- 1.3.4. USCIT Jurisdiction Over Post-Quantum Hardware and International Standards Claims Novel Theory
1.4. Administrative and Regulatory Context (Cross-Ref: Vol. VI, Regulatory)
1.5. International Human Rights Framework (Cross-Ref: Vol. IX, Policy Materials)

Chapter 2: Master Cross-Reference Index

2.1. Exhibit Master List (All Volumes)
- 2.1.1. Scientific Exhibits (P-1 through P-NN) [Cross-Ref: Vol. VIII, Scientific Exhibits]
- 2.1.2. Legal Exhibits (L-1 through L-NN) [Cross-Ref: Vol. V, App.]
- 2.1.3. Administrative Exhibits (A-1 through A-NN) [Cross-Ref: Vol. VI, Admin Record]
- 2.1.4. Technical Exhibits (T-1 through T-NN) [Cross-Ref: Vol. IV, Software App.]
2.2. Figure Index (Unified Canonical, Cross-Ref: Vol. X)
2.3. Table Index (Unified Canonical, Cross-Ref: Vol. X)
2.4. Algorithm and Code Appendix Index (Cross-Ref: Vol. IV, App. C; Vol. VII, Reproducibility)
2.5. Authority Identifier Concordance (CP, SG, DA, SR, LF)

Chapter 3: Statistical Claims Verification and Qualification

3.1. Inventory of All Numerical Claims Across Portfolio
3.2. Status of Supporting Sources
- 3.2.1. Claims with Verified Sources Verified
- 3.2.2. Claims Requiring Additional Support Flagged
- 3.2.3. Claims Removed Pending Verification Quarantined
3.3. Specific Qualifications:
- 3.3.1. "40% Unaccommodated Error Rate" — Under Review; Source Pending
- 3.3.2. "1.15 Million Americans" — Under Review; Source Pending
- 3.3.3. "60% Increase" — Under Review; Source Pending
- 3.3.4. "30,000 Annual Deaths" — Under Review; Source Pending
3.4. Methodology for Statistical Validation (Cross-Ref: Vol. II, Statistical Analysis Plan)

Chapter 4: Terminology and Definitions

4.1. Glossary of Technical Terms (Cross-Ref: Vol. X, Glossary)
4.2. Acronym Index (Cross-Ref: Vol. X, Acronym Index)
4.3. Defined Legal Terms and Proposed Theories
4.4. "Phantom Variant OCR Pipelines" — Definition Pending
- 4.4.1. Proposed Definition (Pending)
- 4.4.2. Supporting Technical Evidence (Cross-Ref: Vol. IV, App. D)
- 4.4.3. Alternative: Removal and Substitution with Concrete Description
4.5. "Supported Workflow Components" — Clarification: Established tools (BWA, minimap2, GATK, DeepVariant) described as integrated workflow stages orchestrated by an R-based layer; not reimplemented in pure R. (Cross-Ref: Vol. IV, Software Architecture; Vol. VII, Reproducibility)

Chapter 5: Filing Compliance and Procedural Verification

5.1. Applicable Filing Rules and Jurisdictional Requirements
- 5.1.1. SCOTUS Rule 33.1 — Jurisdiction and Document Type Under Verification
- 5.1.2. Lower Court Filing Requirements (If Applicable)
- 5.1.3. Administrative Filing Requirements
5.2. Word Count and Formatting Verification Log
5.3. Word-Limit Compliance Statement (Pending Independent Verification)

Chapter 6: Reading Guide by Reviewer Type

Judicial Clerks & Staff Attorneys: Vols. I → V → VI → VII (Litigation & Administrative Record)

Scientific Experts & Amici: Vols. I → II → VIII → IV (Dissertation, Exhibits, Software)

Technical/IT Reviewers: Vols. I → IV → VII → III (Software, Reproducibility, Security)

FDA/Regulatory Reviewers: Vols. I → V → IV → VII (Regulatory, Software, Reproducibility)

International Bodies: Vols. I → IX → II → VIII (Human Rights, Dissertation, Exhibits)

Patent Examiners & Licensing Counsel: Vols. I → III (Patent Specs) → IV (Software) → VII (Reproducibility)

Back Matter

BM-1. Master Bibliography by Subject (Abbreviated; Full: Vol. X)
BM-2. Document Production Log
BM-3. Errata and Revision Tracking
BM-4. Contact Information for Portfolio Administrator

PART C: QUICK-REFERENCE CROSS-WALK

Claim / Term	Location in Portfolio	Status	Authority ID
Genomic info = property (Takings)	Vol. V, Ch. 3; Vol. I, §1.3.1	Proposed Theory	[CP-___]
AI refusal = due process violation	Vol. V, Ch. 3; Vol. I, §1.3.2	Proposed Theory	[DA-___]
SSA must accept AI accommodation	Vol. V, Ch. 4; Vol. I, §1.3.3	Proposed Theory	[SG-___]
USCIT jurisdiction (post-quantum)	Vol. V, Ch. 5; Vol. I, §1.3.4	Proposed Theory	[LF-___]
40% unaccommodated error rate	Vol. V, App.; Vol. I, §3.3.1	Source Pending	[SR-___]
1.15 million Americans	Vol. V, App.; Vol. I, §3.3.2	Source Pending	[SR-___]
60% increase	Vol. V, App.; Vol. I, §3.3.3	Source Pending	[SR-___]
30,000 annual deaths	Vol. V, App.; Vol. I, §3.3.4	Source Pending	[SR-___]
Phantom variant OCR pipelines	Vol. IV, App. D; Vol. I, §4.4	Definition Pending	[CP-___]
BWA/minimap2/GATK as supported workflow	Vol. IV, App. C; Vol. I, §4.5	Clarified	[SR-___]
PRS Workflow (Unified FIG. 14)	Vol. II, IX; PAT. FIG. 14; EXH. 14	Canonical	[SG-___]
ML-KEM / ML-DSA / SLH-DSA Registry	Vol. III, Tables 1–6	Documented	[DA-___]
FDA Traceability Matrix	Vol. V, Table 5; FDA V&V-14	Mapped	[LF-___]

MASTER INDEX — PORTFOLIO TABLE OF CONTENTS